We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Simple Urine Test Diagnoses Bladder Cancer Early

By LabMedica International staff writers
Posted on 03 Jul 2014
A highly-specialized urine test can detect bladder cancer as much as three to six months earlier than an invasive cystoscopy procedure and can help physicians diagnose the disease at an initial stage, when treatment might be more effective. More...


The simple test requires a urine sample and involves the mapping of genetic material in human cells, including specific genes, in the laboratory and fluorescent dyes used in the test can detect genetic abnormalities linked to cancer.

Clinical scientists at Skyline Urology (Torrance, CA, USA) are urging individuals at risk for bladder cancer to undergo the urinary fluorescence in situ hybridization (FISH) test. The primary indicator or symptom of bladder cancer is blood in the urine, which is often detected first on a routine urine analysis test and may not be seen by the naked eye.

Caucasians are about twice as likely to develop bladder cancer as African Americans, and the risk of bladder cancer increases with age. About 9 out of 10 people with bladder cancer are over the age of 55. Bladder cancer is more common in men than in women, and chronic bladder irritation and urinary infections have been linked to bladder cancer.

Cystoscopy is commonly used to diagnose or rule out bladder cancer. In this procedure, the urologist will place a small fiber-optic cystoscope through the opening of the urethra and into the bladder so that the doctor may see the bladder lining. If an abnormal area or growth is seen, it will be biopsied. Cystoscopy can be performed in a doctor's office or in the operating room. A local anesthesia may be used to numb the urethra for the procedure. If a general or spinal anesthesia is used, the procedure is done in the operating room.

Alec S Koo, MD, FACS, a urologist at Skyline Urology, said, “The FISH test uses the latest molecular biology technology and is the first DNA testing used to detect cancer with only a sample of urine. The cost for such testing is higher than standard urine tests because of the sophisticated technology involved. However, when compared to other tests used to diagnose urinary cancer, such as computerized tomography (CT) scan or cystoscopy with anesthesia, the cost of FISH testing is comparable or lower, especially considering the possibility of lost work time following anesthesia.”

Related Links:

Skyline Urology



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.